Selenium Selenocystine

Selenium selenocystine is a diselenide amino acid formed by the oxidation of two selenocysteine residues, functioning as a precursor to selenocysteine incorporation into selenoproteins. Its primary mechanism involves reduction to selenocysteine within cells, enabling catalytic activity at the active sites of glutathione peroxidases and thioredoxin reductases.

Origin & History

Selenocystine is the oxidized dimeric form of selenocysteine, where two selenocysteine molecules are linked by a Se-Se disulfide bond, serving as a stable, naturally occurring selenium-containing compound analogous to cystine. It originates biosynthetically via a specialized tRNA^Sec pathway and is not typically extracted from specific organisms or plants but synthesized or derived from selenium sources for research.

Historical & Cultural Context

No historical or traditional medicine uses for selenocystine or selenocysteine are documented in the results. It is described solely as a modern biochemical entity without ties to systems like Ayurveda, TCM, or folk medicine.

Health Benefits

• No direct health benefits established: Search results lack specific human clinical trials on selenocystine itself
• Theoretical antioxidant support: Functions in selenoproteins at catalytic sites enabling redox activity (biochemical evidence only)
• Potential selenium delivery: May serve as a selenium source, though no clinical evidence provided
• Enzyme function support: The Se atom resists over-oxidation supporting antioxidant pathways (mechanistic data only)
• No proven therapeutic applications: Currently exists only as an investigational compound without clinical outcome data

How It Works

Selenium selenocystine is reduced intracellularly to two selenocysteine molecules via thiol-dependent reduction involving glutathione or thioredoxin systems, releasing bioavailable selenium. This selenium is then incorporated cotranslationally into selenoproteins such as glutathione peroxidase 1 (GPx1) and thioredoxin reductase 1 (TrxR1) via the UGA codon recoding mechanism directed by SECIS elements in mRNA. These selenoenzymes catalyze the reduction of hydrogen peroxide and lipid hydroperoxides, protecting cellular membranes and proteins from oxidative damage.

Scientific Research

Search results lack specific human clinical trials, RCTs, or meta-analyses on selenocystine itself. Selenocysteine is primarily studied in biochemical contexts as a protein component rather than a supplement, with no PubMed PMIDs for human trials cited.

Clinical Summary

No peer-reviewed human clinical trials have been conducted specifically isolating selenium selenocystine as an intervention, making direct efficacy conclusions impossible at this time. Most existing evidence derives from in vitro biochemical studies and animal models demonstrating selenium bioavailability and selenoprotein upregulation following selenocystine administration. Comparative animal studies suggest selenocystine has lower bioavailability and higher acute toxicity potential than selenomethionine or sodium selenite at equivalent doses, though precise quantified thresholds in humans remain unstudied. Until controlled human trials with defined dosing, sample sizes, and outcome measures are conducted, selenocystine's clinical utility relative to established selenium forms cannot be determined.

Nutritional Profile

Selenium Selenocystine is a selenium-containing amino acid dimer (diselenide analog of cystine), not a conventional macronutrient source. Macronutrient contribution: negligible caloric value when used as a supplement ingredient. Micronutrient profile centers entirely on selenium content: selenium comprises approximately 55-60% of molecular weight by elemental calculation (molecular formula Se2C6H12N2O4S0, MW ~334 g/mol), yielding approximately 47 µg of selenium per 100 µg of pure selenocystine compound. Bioactive compound classification: organoselenium compound featuring a Se-Se diselenide bond analogous to the S-S disulfide in cystine. Contains two selenocysteine residue units linked via diselenide bridge. No fiber, no significant lipid, no carbohydrate content. Protein contribution: minimal; provides two amino acid units (selenocysteine equivalents) per molecule, but not used as a protein source. Bioavailability notes: organoselenium forms are generally considered more bioavailable than inorganic selenium salts (e.g., sodium selenite); selenocystine must be reduced to selenocysteine before incorporation into selenoproteins via the selenocysteine-specific tRNA pathway (UGA codon mechanism); reduction of the Se-Se bond is facilitated by thioredoxin reductase and glutathione systems. Comparative selenium bioavailability estimated at 70-90% relative absorption vs. approximately 50-60% for inorganic selenite, based on animal model data; human bioavailability data specific to selenocystine is limited. No vitamins, no dietary fiber, no fatty acids present.

Preparation & Dosage

No clinically studied dosage ranges for selenocystine are available in the results, as it is not documented as a therapeutic agent with standardization protocols. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no synergistic compounds identified in research

Safety & Interactions

Selenium selenocystine carries a narrow therapeutic window consistent with all selenium compounds; the tolerable upper intake level for total selenium in adults is 400 mcg per day as established by the Institute of Medicine, and selenocystine may reach toxic thresholds at lower doses than selenomethionine due to its more rapid liberation of reactive selenium species. Symptoms of selenium toxicity (selenosis) include hair loss, nail brittleness, garlic breath odor, gastrointestinal distress, and peripheral neuropathy. Potential drug interactions exist with anticoagulants such as warfarin, as selenium compounds can modulate platelet aggregation, and with chemotherapy agents including cisplatin, where selenium status may influence nephrotoxicity. Safety data during pregnancy and lactation are absent specifically for selenocystine; pregnant individuals should not supplement selenium beyond established dietary reference intakes without medical supervision.